Formula C18H19N5O4S Density 1.5 g/cm³ ChemSpider ID 8128494 | Molar mass 401.44 g/mol Pubchem 9952884 | |
 | ||
Phase iii trial shows vosaroxin improves overall survival in acute myeloid leukaemia
Vosaroxin (AG-7352, SPC-595, SNS 595, voreloxin) is a topoisomerase II inhibitor causing site-selective DNA damage.It is under phase III clinical trial investigation for acute myelogenous leukemia (AML) and ovarian cancer sponsored by Sunesis.
Contents
Vosaroxin for relapsed aml updates from valor
Mechanism of action
Vosaroxin is a naphthyridine analog of the anticancer quinolone derivatives (AQDs), a class of compounds that has not been used previously for the treatment of cancer. Topoisomerase II enzymes are essential for the survival of eukaryotic cells. Vosaroxin hinders the reunion of topoisomerase II-induced double-strand breaks at selective sites in DNA, resulting in G2 arrest and cell death by apoptosis.
References
Vosaroxin Wikipedia(Text) CC BY-SA